SE9802549D0 - Quinoline derivatives - Google Patents
Quinoline derivativesInfo
- Publication number
- SE9802549D0 SE9802549D0 SE9802549A SE9802549A SE9802549D0 SE 9802549 D0 SE9802549 D0 SE 9802549D0 SE 9802549 A SE9802549 A SE 9802549A SE 9802549 A SE9802549 A SE 9802549A SE 9802549 D0 SE9802549 D0 SE 9802549D0
- Authority
- SE
- Sweden
- Prior art keywords
- fluoro
- chloro
- propyl
- proviso
- hydrogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (34)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9802549A SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Quinoline derivatives |
PL345388A PL199783B1 (pl) | 1998-07-15 | 1999-07-14 | Związki pochodne chinolino-3-karboksyamidu, zawierające je kompozycje farmaceutyczne, sposób ich wytwarzania i ich zastosowanie |
BRPI9912109-3A BR9912109B1 (pt) | 1998-07-15 | 1999-07-14 | compostos derivados de quinolina, composições farmacêuticas, processo para a manufatura de um composto, e, uso de um composto. |
KR10-2000-7014618A KR100516382B1 (ko) | 1998-07-15 | 1999-07-14 | 퀴놀린 유도체 |
ES99933452T ES2205854T3 (es) | 1998-07-15 | 1999-07-14 | Derivados de quinolina. |
CA002336968A CA2336968C (en) | 1998-07-15 | 1999-07-14 | Quinoline derivatives |
HU0103224A HU229427B1 (en) | 1998-07-15 | 1999-07-14 | Quinoline derivatives, process for producing them and pharmaceutical compositions containing them |
PCT/SE1999/001270 WO2000003991A1 (en) | 1998-07-15 | 1999-07-14 | Quinoline derivatives |
IL14034699A IL140346A0 (en) | 1998-07-15 | 1999-07-14 | Quinoline derivatives |
RU2001104342/04A RU2213733C2 (ru) | 1998-07-15 | 1999-07-14 | Производные хинолина, способ их получения (варианты), фармацевтическая композиция и способ лечения с их использованием |
APAP/P/2001/002041A AP1366A (en) | 1998-07-15 | 1999-07-14 | Quinoline derivatives. |
EP99933452A EP1095021B1 (en) | 1998-07-15 | 1999-07-14 | Quinoline derivatives |
YUP-15/01A RS50128B (sr) | 1998-07-15 | 1999-07-14 | Derivati hinolina |
CNB998085987A CN1157378C (zh) | 1998-07-15 | 1999-07-14 | 喹啉衍生物 |
PT99933452T PT1095021E (pt) | 1998-07-15 | 1999-07-14 | Derivados de quinolina |
DK99933452T DK1095021T3 (da) | 1998-07-15 | 1999-07-14 | Quinolinderivater |
OA00100011A OA11906A (en) | 1998-07-15 | 1999-07-14 | Quinoline derivatives. |
NZ508923A NZ508923A (en) | 1998-07-15 | 1999-07-14 | N-phenyl-1-Methyl-2-oxo-quinoline-3-carboxamide derivatives, pharmaceuticals thereof and their use in therapy |
AU49504/99A AU751103B2 (en) | 1998-07-15 | 1999-07-14 | Quinoline derivatives |
IDW20010331A ID27423A (id) | 1998-07-15 | 1999-07-14 | Turunan kuinolin |
JP2000560098A JP4045070B2 (ja) | 1998-07-15 | 1999-07-14 | キノリン誘導体 |
CZ20010094A CZ300229B6 (cs) | 1998-07-15 | 1999-07-14 | Deriváty chinolinu |
MEP-2008-574A ME00374B (me) | 1998-07-15 | 1999-07-14 | Derivati hinolina |
EEP200100010A EE04673B1 (et) | 1998-07-15 | 1999-07-14 | Kinoliini derivaadid, nende valmistamine ja kasutamine ravimina ning neid sisaldavad farmatseutilised kompositsioonid |
TR2001/00087T TR200100087T2 (tr) | 1998-07-15 | 1999-07-14 | Kinolin türevleri |
UA2000127299A UA64791C2 (en) | 1998-07-15 | 1999-07-14 | Quinoline derivatives, a method for the preparation thereof, a pharmaceutical composition and a method for treatment of diseases resulting from pathological inflammation or autoimmunity |
DE69911415T DE69911415T2 (de) | 1998-07-15 | 1999-07-14 | Chinolinderivate |
AT99933452T ATE250036T1 (de) | 1998-07-15 | 1999-07-14 | Chinolinderivate |
IL140346A IL140346A (en) | 1998-07-15 | 2000-12-14 | Quinoline derivatives, pharmaceutical preparations containing them and a process for their preparation |
IS5775A IS2208B (is) | 1998-07-15 | 2000-12-18 | Quinoline afleiður |
ZA200007593A ZA200007593B (en) | 1998-07-15 | 2000-12-18 | Quinoline Derivatives. |
NO20010211A NO317601B1 (no) | 1998-07-15 | 2001-01-12 | Kinolinderivater |
HR20010039A HRP20010039B1 (en) | 1998-07-15 | 2001-01-12 | Quinoline derivatives |
HK01104765A HK1035715A1 (en) | 1998-07-15 | 2001-07-10 | Quinoline derivatives |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9802549A SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Quinoline derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
SE9802549D0 true SE9802549D0 (sv) | 1998-07-15 |
Family
ID=20412093
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE9802549A SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Quinoline derivatives |
Country Status (33)
Country | Link |
---|---|
EP (1) | EP1095021B1 (sv) |
JP (1) | JP4045070B2 (sv) |
KR (1) | KR100516382B1 (sv) |
CN (1) | CN1157378C (sv) |
AP (1) | AP1366A (sv) |
AT (1) | ATE250036T1 (sv) |
AU (1) | AU751103B2 (sv) |
BR (1) | BR9912109B1 (sv) |
CA (1) | CA2336968C (sv) |
CZ (1) | CZ300229B6 (sv) |
DE (1) | DE69911415T2 (sv) |
DK (1) | DK1095021T3 (sv) |
EE (1) | EE04673B1 (sv) |
ES (1) | ES2205854T3 (sv) |
HK (1) | HK1035715A1 (sv) |
HR (1) | HRP20010039B1 (sv) |
HU (1) | HU229427B1 (sv) |
ID (1) | ID27423A (sv) |
IL (2) | IL140346A0 (sv) |
IS (1) | IS2208B (sv) |
ME (1) | ME00374B (sv) |
NO (1) | NO317601B1 (sv) |
NZ (1) | NZ508923A (sv) |
OA (1) | OA11906A (sv) |
PL (1) | PL199783B1 (sv) |
PT (1) | PT1095021E (sv) |
RS (1) | RS50128B (sv) |
RU (1) | RU2213733C2 (sv) |
SE (1) | SE9802549D0 (sv) |
TR (1) | TR200100087T2 (sv) |
UA (1) | UA64791C2 (sv) |
WO (1) | WO2000003991A1 (sv) |
ZA (1) | ZA200007593B (sv) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0002320D0 (sv) * | 1999-10-25 | 2000-06-21 | Active Biotech Ab | Malignant tumors |
US6395750B1 (en) * | 1999-10-25 | 2002-05-28 | Active Biotech Ab | Drugs for the treatment of malignant tumors |
AU2003242127A1 (en) * | 2002-06-05 | 2003-12-22 | Institute Of Medicinal Molecular Design, Inc. | Inhibitors against the activation of ap-1 and nfat |
EA011707B1 (ru) * | 2002-06-11 | 2009-04-28 | Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. | Лекарственное средство для лечения нейродегенеративных заболеваний |
US8314124B2 (en) | 2004-02-06 | 2012-11-20 | Active Biotech Ab | Crystalline salts of quinoline compounds and methods for preparing them |
SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
SE0401578D0 (sv) * | 2004-06-18 | 2004-06-18 | Active Biotech Ab | Novel compounds |
PT1937642E (pt) | 2005-10-19 | 2014-11-25 | Teva Pharma | Cristais de sódio de laquinimod, e processos para o fabrico dos mesmos |
EP2035001B1 (en) | 2006-06-12 | 2011-11-09 | Teva Pharmaceutical Industries Limited | Stable laquinimod preparations |
WO2008113006A1 (en) * | 2007-03-14 | 2008-09-18 | Xenon Pharmaceuticals Inc. | Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions |
US8178127B2 (en) | 2007-12-20 | 2012-05-15 | Teva Pharmaceuticals Industries, Ltd. | Stable laquinimod preparations |
KR20160079147A (ko) | 2008-09-03 | 2016-07-05 | 테바 파마슈티컬 인더스트리즈 리미티드 | 면역 기능을 지닌 2―옥소―1,2―다이하이드로―퀴놀린 조절제 |
DE102010048788A1 (de) | 2009-02-13 | 2011-05-19 | Amw Gmbh | Transdermales System mit Immunmodulator |
DE102009008851A1 (de) | 2009-02-13 | 2010-08-19 | Amw Gmbh | Transdermales System mit Immunmodulator |
AU2010276748A1 (en) | 2009-07-30 | 2012-03-15 | Teva Pharmaceutical Industries Ltd. | Treatment of Crohn's disease with laquinimod |
HUE029983T2 (en) | 2009-08-10 | 2017-04-28 | Teva Pharma | Treatment of BDNF-related diseases with laquinimod |
DE102010026879A1 (de) | 2010-02-11 | 2011-08-11 | AMW GmbH, 83627 | Transdermales System mit Immunmodulator |
MX337614B (es) | 2010-03-03 | 2016-03-10 | Teva Pharma | Tratamiento de lupus nefritis usando laquinimod. |
KR20130014523A (ko) | 2010-03-03 | 2013-02-07 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드 및 메토트렉세이트의 병용에 의한 류마티스 관절염의 치료 |
KR20130092558A (ko) | 2010-07-09 | 2013-08-20 | 테바 파마슈티컬 인더스트리즈 리미티드 | 중수소화된 n-에틸-n-페닐-1,2-다이하이드로-4-하이드록시-5-클로로-1-메틸-2-옥소퀴놀린-3-카복스아마이드, 그의 염 및 용도 |
CN103189357B (zh) * | 2010-08-27 | 2015-11-25 | 格吕伦塔尔有限公司 | 作为kcnq2/3调节剂的取代的2-氧代-和2-硫代-二氢喹啉-3-甲酰胺 |
BR112013007850A2 (pt) | 2010-10-14 | 2016-06-07 | Immunahr Ab | 1,2-diidro-4-hidróxi-2-oxo-quinolina-3-carboxanilidas como ativadores de ahr |
EP2537517A1 (en) * | 2011-06-22 | 2012-12-26 | Active Biotech AB | Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide |
AU2012322706A1 (en) | 2011-10-12 | 2014-05-22 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
CN104093310A (zh) | 2012-02-03 | 2014-10-08 | 泰华制药工业有限公司 | 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途 |
CN104114172A (zh) | 2012-02-16 | 2014-10-22 | 泰华制药工业有限公司 | N-乙基-n-苯基-1,2-二氢-4,5-二-羟基-1-甲基-2-氧代-3-喹啉甲酰胺、其制备和用途 |
TW201350467A (zh) | 2012-05-08 | 2013-12-16 | Teva Pharma | N-乙基-4-羥基-1-甲基-5-(甲基(2,3,4,5,6-五羥基己基)胺基)-2-側氧-n-苯基-1,2-二氫喹啉-3-甲醯胺 |
TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療gaba媒介之疾病之拉喹莫德(laquinimod) |
MX2015005632A (es) | 2012-11-07 | 2016-02-05 | Teva Pharma | Sales de amina de laquinimod. |
JP5868839B2 (ja) | 2012-12-27 | 2016-02-24 | 三菱重工業株式会社 | チャー払出管 |
MX2015011627A (es) | 2013-03-14 | 2016-05-16 | Teva Pharma | Cristales de laquinimod sodico y proceso mejorado para la elaboracion de los mismos. |
KR20170005434A (ko) | 2014-04-29 | 2017-01-13 | 테바 파마슈티컬 인더스트리즈 리미티드 | 높은 장애 상태를 갖는 재발-완화형 다발성 경화증(rrms) 환자 치료용 라퀴니모드 |
CN105367492B (zh) * | 2014-08-28 | 2018-07-03 | 杭州普晒医药科技有限公司 | 他喹莫德的晶型及其制备方法、其药物组合物和用途 |
EA030948B1 (ru) | 2014-09-23 | 2018-10-31 | Эктив Байотек Аб | Хинолинкарбоксамиды для применения в лечении множественной миеломы |
PL3180005T3 (pl) | 2014-11-19 | 2018-06-29 | Active Biotech Ab | Chinolinokarboksyamidy do stosowania w leczeniu białaczki |
EP3067062A1 (en) | 2015-03-13 | 2016-09-14 | Ipsen Pharma S.A.S. | Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament |
WO2018105943A1 (ko) * | 2016-12-07 | 2018-06-14 | 순천향대학교 산학협력단 | 폐섬유증 또는 천식의 치료 또는 완화용 약학 조성물 |
US20230085883A1 (en) | 2020-03-03 | 2023-03-23 | Active Biotech Ab | Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy |
KR20230043916A (ko) | 2020-07-23 | 2023-03-31 | 에라스무스 유니버시티 메디컬 센터 로테르담 | 골수증식성 신생물의 새로운 치료학적 표적으로서 s100 단백질 |
EP4277628A1 (en) | 2021-01-18 | 2023-11-22 | Active Biotech AB | Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome |
US20240285532A1 (en) | 2021-05-25 | 2024-08-29 | Active Biotech Ab | A plurality of tasquinimod particles and use thereof |
KR20240029029A (ko) | 2021-07-02 | 2024-03-05 | 액티브 바이오테크 에이비 | 타스퀴니모드를 함유한 약학적 제품 및 이러한 제품의 순도 평가 방법 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE52670B1 (en) * | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
GB9108547D0 (en) * | 1991-04-22 | 1991-06-05 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
SE469368B (sv) * | 1991-10-09 | 1993-06-28 | Kabi Pharmacia Ab | Ny anvaendning av linomide foer tillverkning av laekemedel foer behandling av multiple sclerosis (ms) |
SE9201076L (sv) * | 1992-04-06 | 1993-10-07 | Shimon Slavin | Användningen av gamla läkemedel för behandling av diabetes |
JPH07224040A (ja) * | 1994-02-07 | 1995-08-22 | Fujisawa Pharmaceut Co Ltd | キノリン誘導体 |
GB9404378D0 (en) * | 1994-03-07 | 1994-04-20 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
SE9400810D0 (sv) * | 1994-03-10 | 1994-03-10 | Pharmacia Ab | New use of Quinoline-3-carboxamide compounds |
SE9400809D0 (sv) * | 1994-03-10 | 1994-03-10 | Pharmacia Ab | New use of quinoline-3-carboxamide compounds |
GB2290786A (en) * | 1994-06-30 | 1996-01-10 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
-
1998
- 1998-07-15 SE SE9802549A patent/SE9802549D0/sv unknown
-
1999
- 1999-07-14 UA UA2000127299A patent/UA64791C2/uk unknown
- 1999-07-14 IL IL14034699A patent/IL140346A0/xx active IP Right Grant
- 1999-07-14 EE EEP200100010A patent/EE04673B1/xx unknown
- 1999-07-14 ES ES99933452T patent/ES2205854T3/es not_active Expired - Lifetime
- 1999-07-14 RU RU2001104342/04A patent/RU2213733C2/ru not_active IP Right Cessation
- 1999-07-14 HU HU0103224A patent/HU229427B1/hu not_active IP Right Cessation
- 1999-07-14 DK DK99933452T patent/DK1095021T3/da active
- 1999-07-14 OA OA00100011A patent/OA11906A/en unknown
- 1999-07-14 CA CA002336968A patent/CA2336968C/en not_active Expired - Fee Related
- 1999-07-14 JP JP2000560098A patent/JP4045070B2/ja not_active Expired - Fee Related
- 1999-07-14 ME MEP-2008-574A patent/ME00374B/me unknown
- 1999-07-14 AU AU49504/99A patent/AU751103B2/en not_active Ceased
- 1999-07-14 EP EP99933452A patent/EP1095021B1/en not_active Expired - Lifetime
- 1999-07-14 BR BRPI9912109-3A patent/BR9912109B1/pt not_active IP Right Cessation
- 1999-07-14 CZ CZ20010094A patent/CZ300229B6/cs not_active IP Right Cessation
- 1999-07-14 WO PCT/SE1999/001270 patent/WO2000003991A1/en not_active Application Discontinuation
- 1999-07-14 DE DE69911415T patent/DE69911415T2/de not_active Expired - Lifetime
- 1999-07-14 AP APAP/P/2001/002041A patent/AP1366A/en active
- 1999-07-14 PL PL345388A patent/PL199783B1/pl unknown
- 1999-07-14 ID IDW20010331A patent/ID27423A/id unknown
- 1999-07-14 AT AT99933452T patent/ATE250036T1/de active
- 1999-07-14 PT PT99933452T patent/PT1095021E/pt unknown
- 1999-07-14 KR KR10-2000-7014618A patent/KR100516382B1/ko not_active IP Right Cessation
- 1999-07-14 CN CNB998085987A patent/CN1157378C/zh not_active Expired - Fee Related
- 1999-07-14 RS YUP-15/01A patent/RS50128B/sr unknown
- 1999-07-14 TR TR2001/00087T patent/TR200100087T2/xx unknown
- 1999-07-14 NZ NZ508923A patent/NZ508923A/xx not_active IP Right Cessation
-
2000
- 2000-12-14 IL IL140346A patent/IL140346A/en not_active IP Right Cessation
- 2000-12-18 ZA ZA200007593A patent/ZA200007593B/xx unknown
- 2000-12-18 IS IS5775A patent/IS2208B/is unknown
-
2001
- 2001-01-12 HR HR20010039A patent/HRP20010039B1/xx not_active IP Right Cessation
- 2001-01-12 NO NO20010211A patent/NO317601B1/no not_active IP Right Cessation
- 2001-07-10 HK HK01104765A patent/HK1035715A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SE9802549D0 (sv) | Quinoline derivatives | |
SE9801474D0 (sv) | Quinoline Derivatives | |
AP1425A (en) | Quinoline derivatives. | |
TR200000837A2 (tr) | Anti-kanser bileşimleri hazırlamak için işlem ve ara maddeler. | |
ATE37179T1 (de) | Dihydropyridazinone. | |
ATE139233T1 (de) | Annelierte thiophen-derivate, ihre herstellung und verwendung | |
NZ336302A (en) | Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of benign prostatic hyperplasia | |
CA2205274A1 (en) | Novel 2,3 disubstituted-(5,6)-heteroarylfused-pyrimidine-4-ones | |
BR0213731A (pt) | Compostos de silìcio | |
EA200400219A1 (ru) | Производные хинолина и их использование в качестве противоопухолевых средств | |
ATE216233T1 (de) | Indolditerpen alkaloide | |
EA200101050A1 (ru) | Замещенные бензолактамные соединения | |
DK1082116T3 (da) | Anvendelse af 4-piperidinmethanolderivater til behandling af neurologiske sygdomme | |
MXPA04000615A (es) | Compuestos utiles para el tratamiento o la prevencion de enfermedades mediadas por alfa-2b-adrenoceptor. | |
SE0401578D0 (sv) | Novel compounds | |
IT1205640B (it) | Nuovi composti ad attivita' antiinfiammatoria,procedimento per la loro preparazione e composizioni farmaceutiche che li contengono | |
ATE56442T1 (de) | 2,6-piperazin-dion-derivate, ihre verfahren zur herstellung und sie enthaltende pharmazeutische zusammensetzungen. | |
SE0400440D0 (sv) | Novel Cinnamic Amides | |
DK0660840T3 (da) | Phosphono-substituerede tetrazolderivater. | |
ATE264320T1 (de) | 5-aminoalkyl- und 5-aminocarbonylsubstituierte indole | |
MX9601953A (es) | Nuevo compesto derivados de 5h-tiazolo [3,2-a] pirimidin-5-ona. | |
MX9705144A (es) | Uso de un compuesto de carboestirilo para preparar un inhibidor de la produccion o secrecion del factor de necrosis tumoral alfa. |